Company logo

ADMP - Adamis Pharmaceuticals Corporation

NASDAQ -> Healthcare -> Drug Manufacturers—Specialty & Generic
San Diego, United States
Type: Equity

ADMP price evolution
ADMP
(in millions $) 30 Jun 2023 31 Mar 2023 31 Jan 2023 30 Sep 2022
Current assets
Cash $0.67 $3.13 $1.11 $2.45
Short term investments
Net receivables $0.02 $0.02 $1.09 $1.55
Inventory $0.66 $0.66 $1.24 $1.09
Total current assets $3.45 $7.55 $9.27 $10.09
Long term investments
Property, plant & equipment $1.29 $1.48 $1.61 $2
Goodwill & intangible assets
Total noncurrent assets $1.3 $1.53 $1.66 $2.05
Total investments
Total assets $4.75 $9.08 $10.93 $12.14
Current liabilities
Accounts payable $11.37 $9.78 $7.94 $5.3
Deferred revenue $0.34 $0.2 $0.21 $0.21
Short long term debt $0.16 $0.25 $0.34 $0.37
Total current liabilities $15.01 $12.95 $11.4 $8.87
Long term debt $0.06
Total noncurrent liabilities $1.24 $5.65 $0.19 $0.26
Total debt $0.16 $0.25 $0.34 $0.43
Total liabilities $16.24 $18.6 $11.58 $9.13
Shareholders' equity
Retained earnings -$322.08 -$313.51 -$304.56 -$301.24
Other shareholder equity
Total shareholder equity -$11.83 -$9.68 -$0.81 $2.85
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $1.11 $23.25 $6.86 $8.81
Short term investments
Net receivables $1.09 $5.9 $1.09 $1.88
Inventory $1.24 $0.42 $3.12 $2.06
Total current assets $9.27 $35.2 $12.52 $13.88
Long term investments
Property, plant & equipment $1.61 $2.99 $11.13 $13.54
Goodwill & intangible assets $7.16 $18.77
Total noncurrent assets $1.66 $3.09 $18.34 $33.96
Total investments
Total assets $10.93 $38.3 $30.87 $47.84
Current liabilities
Accounts payable $7.94 $3.75 $3.49 $4.27
Deferred revenue $0.21 $0.85 $0.95 $0.92
Short long term debt $0.34 $0.35 $4.86 $2.6
Total current liabilities $11.4 $11.22 $19.93 $10.21
Long term debt $0.34 $2 $1.48
Total noncurrent liabilities $0.19 $1.19 $7.44 $1.59
Total debt $0.34 $0.69 $6.86 $4.08
Total liabilities $11.58 $12.42 $27.37 $11.8
Shareholders' equity
Retained earnings -$304.56 -$278.09 -$229.91 -$182.31
Other shareholder equity -$0.01 -$0.01
Total shareholder equity -$0.81 $25.88 $3.5 $36.04
(in millions $) 30 Jun 2023 31 Mar 2023 31 Dec 2022 30 Sep 2022
Revenue
Total revenue $0.01 $1.45 $2.15 $1.51
Cost of revenue $0.36 $1.79 $2.48 $1.65
Gross Profit -$0.35 -$0.34 -$0.33 -$0.14
Operating activities
Research & development $0.38 $1.31 $0.86 $1.98
Selling, general & administrative $4.03 $4.78 $3.15 $2.51
Total operating expenses $10.95 $6.09 $4.01 $4.49
Operating income -$11.3 -$6.43 -$4.34 -$4.63
Income from continuing operations
EBIT -$8.53 -$8.94 -$3.75 -$4.7
Income tax expense $0
Interest expense $0.05 -$0.42 -$0.3
Net income
Net income -$8.57 -$8.94 -$3.33 -$4.4
Income (for common shares) -$8.57 -$8.94 -$3.33 -$4.4
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $4.76 $2.21 $16.53 $22.11
Cost of revenue $6.19 $6.87 $14.89 $15.48
Gross Profit -$1.43 -$4.66 $1.63 $6.64
Operating activities
Research & development $10.38 $11.26 $8.28 $10.38
Selling, general & administrative $13.25 $16.14 $30.58 $25.29
Total operating expenses $23.63 $27.41 $51.41 $35.99
Operating income -$25.06 -$32.07 -$49.78 -$29.35
Income from continuing operations
EBIT -$26.52 -$45.82 -$49.23 -$29.17
Income tax expense $0 $0 $0 $0.01
Interest expense -$0.04 $0.01 $0.16 $0.12
Net income
Net income -$26.48 -$45.83 -$49.39 -$29.31
Income (for common shares) -$26.48 -$45.83 -$49.39 -$29.31
(in millions $) 30 Jun 2023 31 Mar 2023 31 Dec 2022 30 Sep 2022
Net income -$8.57 -$8.94 -$3.33 -$4.4
Operating activities
Depreciation $0.09 $0.11 $0.37 $0.4
Business acquisitions & disposals $0.14 $0.01 $0.17 $0.99
Stock-based compensation $0.05 $0.07 -$0.33 $0.07
Total cash flows from operations -$2.57 -$1.55 -$1.52 -$7.5
Investing activities
Capital expenditures -$0.09 -$0.21
Investments
Total cash flows from investing $0.14 $0.84 $0.16 $0.78
Financing activities
Dividends paid
Sale and purchase of stock $3
Net borrowings
Total cash flows from financing $0 $2.72 $0.28
Effect of exchange rate
Change in cash and equivalents -$2.43 $2.02 -$1.37 -$6.43
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$26.48 -$45.83 -$49.39 -$29.31
Operating activities
Depreciation $1.48 $1.44 $3.61 $2.96
Business acquisitions & disposals $4.09
Stock-based compensation -$0.34 $1.98 $4.42 $5.87
Total cash flows from operations -$25.9 -$37.79 -$20.9 -$19.89
Investing activities
Capital expenditures -$0.68 -$1.22 -$0.7 -$2.87
Investments
Total cash flows from investing $3.48 $0.28 -$0.95 -$2.87
Financing activities
Dividends paid
Sale and purchase of stock $57.6 $18.23 $12.79
Net borrowings $3.1 -$0.5
Total cash flows from financing $0.28 $53.94 $19.89 $12.29
Effect of exchange rate
Change in cash and equivalents -$22.13 $16.43 -$1.96 -$10.46
Fundamentals
Market cap $1.37M
Enterprise value $854.28K
Shares outstanding 2.79M
Revenue $5.12M
EBITDA -$24.95M
EBIT -$25.92M
Net Income -$25.24M
Revenue Q/Q -82.57%
Revenue Y/Y 543.65%
P/E ratio -0.05
EV/Sales 0.17
EV/EBITDA -0.03
EV/EBIT -0.03
P/S ratio 0.27
P/B ratio -0.12
Book/Share -4.24
Cash/Share 0.24
EPS -$9.05
ROA -273.69%
ROE 518.62%
Debt/Equity -14.33
Net debt/EBITDA -0.62
Current ratio 0.23
Quick ratio 0.19